About Memo Therapeutics
Memo Therapeutics is a Healthcare company based in Schlieren (Switzerland) founded in 2012, and was acquired by Ipsen in July 2026. Developer of antibodies for treating infectious diseases and cancer. Memo Therapeutics has raised $97.24 million across 7 funding rounds from investors including Zurcher Kantonalbank, Fresenius Medical Care and Ipsen. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.
Company details
Memo Therapeutics was founded in 2012 in Schlieren, Switzerland, within the biotechnology sector. Antibodies targeting infectious diseases and cancer are developed through proprietary microfluidic single-cell molecular cloning and screening technologies. These methods facilitate antibody production. Operations center on advancing therapeutic candidates, with the lead product directed toward infectious disease treatment. Geographic focus remains in Switzerland for research and development.
- Headquarters Schlieren, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website memo-therapeutics.com
- Social LinkedIn
- Acquired by Ipsen (Jul 2026)
- Total Equity Funding$97.24M (USD)
in 7 rounds
- Latest Funding Round$22.08M (USD), Series C
May 2024
- InvestorsZurcher Kantonalbank
& 16 more
- Acquired byIpsen
(Jul 2026)
Funding Insights of Memo Therapeutics
Memo Therapeutics has successfully raised a total of $97.24M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $22.08 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $97.24M
- Total Rounds 7
- Last Round Series C — $22.08M
- First Round $2.39M
(Jul 2015)
- Investors Count 16
All 7 funding rounds of Memo Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $22.08M | Series C | – | – | |
| Nov 2023 | $27.5M | Series C | – | Pureos Bioventures | |
| Feb 2022 | $24.87M | Series B | – | Swisscanto | |
| Dec 2021 | $11.4M | Grant | – | – | – |
| Nov 2020 | $15.42M | Series B | – | Swisscanto | |
| May 2018 | $4.99M | Series A | – | Schroders Capital, Verve Ventures | |
| Jul 2015 | $2.39M | Series A | – | – |
17 investors in total: 17 institutional.
Investors in Memo Therapeutics
Memo Therapeutics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Zurcher Kantonalbank, Fresenius Medical Care and Ipsen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ysios Capital is recognized as a leading life sciences investor. | ysioscapital.com | Barcelona, Spain | ||
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Venture capital is invested in innovative drug development companies. | pureosbio.com | Pfäffikon, Switzerland | ||
Life sciences-focused VC firm investing in Europe and Canada | 2007 | vesaliusbiocapital.com | Strassen, Luxembourg | |
Venture capital is deployed for global health technology innovations. | adjuvantcapital.com | New York City, USA | ||
Venture capital firm focused on science and tech-driven startups | verve.vc | Berlin, Germany | ||
Early-stage investments are directed toward ICT and health tech startups. | redalpine.com | Zurich, Switzerland | ||
A European life sciences venture capital investor is operated. | 2017 | vesaliusbiocapital-3.com | Strassen, Luxembourg | |
Jaquet Partners is engaged in sustainable investments as a family office. | jaquetpartners.com | Basel, Switzerland | ||
Early stage biotech and medtech investments are facilitated. | berninabioinvest.com |
Investor details for Memo Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Memo Therapeutics
21 people are tracked at Memo Therapeutics (6 in leadership, 9 in board & advisors, 6 in team).
| Name | Role | Group |
|---|---|---|
Matthias Hillenbrand | Director Of Virology | Leadership |
Jürgen Beck | CMO | Leadership |
Muazzam K. | Head Of CMC | Leadership |
Lars Spenger | Head, Finance | Leadership |
Matthieu Delincé | Director, Head Of Oncology Research | Leadership |
Kristie Bass Clemmer | Vice President, Clinical Operations | Leadership |
Stefan Kaufmann | Scientific Advisor | Board & advisors |
Michael Hodges | Scientific Advisor | Board & advisors |
Bodo Plachter | Scientific Advisor | Board & advisors |
Elias Papatheodorou | Independent Chairman | Board & advisors |
Philippe Dro | Investor Representative | Board & advisors |
Andreas Wüpper | Investor Representative | Board & advisors |
Robert Schier | Swisscanto, Investor Representative | Board & advisors |
Christian Schneider | Investor Representative | Board & advisors |
Thomas Taapken | Independent Board Member | Board & advisors |
Christoph Esslinger | CSO, Board Member | Team |
Gerald P. Parzmair | SVP Development | Team |
Jemima Seidenberg | Scientist | Team |
Barbara Eicher | Scientist Antibody Development | Team |
Benedikt Stöckli | Wissenschaftlicher Mitarbeiter | Team |
1 more people are available in the full profile.
Complete people profiles for Memo Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Memo Therapeutics
4 dated milestones of Memo Therapeutics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Memo Therapeutics is founded.
- Funding First funding round of $2.4M.
- Funding Latest funding round, Series C, of $22.1M.
- Exit Acquired by Ipsen.
Web traffic of Memo Therapeutics
The website of Memo Therapeutics (memo-therapeutics.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 66.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Memo Therapeutics
Complete news archive for Memo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Memo Therapeutics
Memo Therapeutics was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Memo Therapeutics is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Memo Therapeutics is a funded company, having raised a total of $97.24M across 7 funding rounds to date. The company's 1st funding round was a Series A of $2.39M, raised on Jul 2015.
Memo Therapeutics was founded in 2012 in Schlieren, Switzerland, within the biotechnology sector. Antibodies targeting infectious diseases and cancer are developed through proprietary microfluidic single-cell molecular cloning and screening technologies. These methods facilitate antibody production. Operations center on advancing therapeutic candidates, with the lead product directed toward infectious disease treatment. Geographic focus remains in Switzerland for research and development.
Memo Therapeutics has 17 investors. Key investors include Zurcher Kantonalbank, Fresenius Medical Care, Ipsen, Swisscanto, and Kurma Partners.
Yes. Memo Therapeutics was acquired by Ipsen in July 2026.